Skip to content
FIG. 1 · Adjustable blood pressure cuff and method of using sameLloyd Marks' U.S. Patent 5,746,213 · 1998

For investors

Medical Device Due Diligence for Investors

A medical-device pitch rests on technical and clinical assumptions that are hard to check from a deck: that the device works as described, that clinicians need it, that the evidence supports it, and that nothing simpler already does the job. I review those assumptions for investors so the investment decision rests on a clearer view of the technology.

B.S., electrical engineering
MIT
University of Michigan
MD

Separating the technology from the financial case

A useful review keeps two things apart. One is the evidence about the device itself: how it works, how it would be used, what the clinical data show, what it competes with, and what has to happen for clinicians and buyers to adopt it. The other is the financial case built on top of that evidence: market size, pricing, projections and returns.

My review concentrates on the first and checks whether the second is built on assumptions the first can support. Valuation, deal terms and the investment decision remain with you and your financial and legal advisers.

Questions a review can clarify

Does the technology do what is claimed?

Whether the principle of operation is sound, whether the engineering is realistic for the intended setting, and what remains unproven.

Is the need real, and whose need is it?

Who uses the device, who decides to buy it, and whether it fits the way care is actually delivered.

How strong is the clinical evidence?

Whether studies were designed to answer the question that matters, whether results have been portrayed accurately, and what further evidence a buyer or partner is likely to expect.

What are the direct and indirect alternatives?

Competing devices, existing practices and simpler approaches that a new device has to beat.

What should you ask patent counsel?

A technical reading of the company's patents and the nearby art can identify questions for your IP counsel. It is not an opinion on validity, scope or freedom to operate.

Do the business plan and projections match the technical picture?

Whether adoption timelines, development milestones and evidence plans in the business plan are consistent with what the technology and clinical evidence support.

What you receive

The form of the output is agreed when the work is scoped. It can be a discussion of findings, a written summary, or a list of open questions and evidence gaps to raise with management. Findings describe the technology and the evidence; whether the company succeeds depends on much more than either.

Why an engineer-physician-inventor

I combine training in electrical engineering and medicine with an MBA, and I have been on the other side of the table: as an inventor and as the founder of my own medical-device startup, for which I wrote the business plan and pro forma. I have also done acquisition diligence myself: Datascope (now Mindray) sent me to evaluate a startup's automated external defibrillator for in-hospital use, and after reviewing the data and studying the device I advised against the acquisition.

See About for my background and Resources for the current sample assessment once it is published.

What would make the device stronger

When I review an invention I nearly always come back with concrete ideas for making it better, as well as a view of its prospects. For an investor, that adds a second answer to the review: not only whether the technology holds up, but what changes would make it a stronger investment. In the sample assessment of a robotic blood-drawing device, that meant pointing toward a handheld device combining near-infrared vein imaging with ultrasound guidance.

How a review starts

  1. Describe the opportunity in general terms

    The clinical area, the company's stage, the decision you face and your timing. Leave out confidential company information.

  2. Arrange confidential access separately

    Access to company materials, and any confidentiality terms that cover it, is arranged directly before anything confidential is shared. The contact form does not create a confidentiality agreement.

  3. Agree the questions and the output

    The review is scoped to the questions that would change your decision, with the form of the output agreed in advance.

Where my role ends

  • I am not a securities, investment or financial adviser and do not recommend investments, value companies or predict returns.
  • A review of projections tests their technical and clinical assumptions; the financial model itself stays with your analysts.
  • Legal opinions on patents and contracts come from your counsel.
  • Please keep confidential data-room material off this website.

Considering a medical-device investment?

Start with a general description of the opportunity and the decision ahead. The first consultation is free.

Questions and answers

Will you tell us whether to invest?

No. The review clarifies the technical and clinical picture and the questions it raises. The investment decision, valuation and terms stay with you and your advisers.

Does the review cover the financial model?

It checks whether the assumptions feeding the model, such as development milestones, evidence plans and adoption, are consistent with the technology and the clinical evidence. It does not audit the model or the company's financial statements.

Does 510(k) clearance mean a device has strong clinical evidence?

Not by itself. A 510(k) clearance is an FDA finding that a device is substantially equivalent to one already legally marketed, and many cleared devices have little clinical data of their own. A review asks what evidence actually exists for the claims in the pitch. The due diligence checklist covers this in more detail.

What do you look for in a company's clinical evidence?

Who was studied and how many, what the device was compared with, whether the outcomes matter to clinicians and payers, who ran the study, and whether the results are published or only summarized. The question is whether the evidence supports the specific claims the company is making.

Can the review include the company's patents?

A technical reading of the patents can highlight questions for your IP counsel. Opinions on validity, infringement or freedom to operate come from counsel.

Is there an example of the work?

Not yet. A sample will be added to Resources once one is approved for publication. Until then, the medical device due diligence checklist describes the method, and the first conversation can cover how a review of your question would be structured.

Is this different from due diligence for an acquisition?

This page is for investors deciding whether to fund a company. Companies weighing an acquisition or an outside technology can see Corporations.